# NCT06691685 (NCT06691685)

> A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.

No report yet. It can be ordered.

- Drugs tested: ESO-T01
- Indication: relapsed/refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06691685
- Phase: EARLY_PHASE1
- Status: SUSPENDED
- Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Conditions: Multiple Myeloma
- Interventions: ESO-T01 Injection
- Enrollment: 24
- Primary outcome: Cytokine release syndrome (CRS)
- Primary outcome: Dose-limiting toxicities (DLTs)
- Primary outcome: immune cell-associated immune effector cell-associated neurotoxicity syndrome (ICANS)
- Primary outcome: Treatment-associated adverse effects (AEs)

## Indexed commentary on NCT06691685 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06691685